Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study

Rheumatology

Volumn 44, Issue 12, 2005, Pages 1555-1558

  Collantes Estevez, E ^f   Munoz Villanueva M C ^f   Zarco, P ^a   Torre Alonso, J C ^b   Gratacos J ^c   Gonzalez C ^d   Sanmarti R ^e   Canete J D ^e  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b Monte Naranco Hospital   (Spain)

^c HOSPITAL DE SABADELL   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Ankylosing spondylitis; Anti tumour necrosis factor ; Infliximab; Spondyloarthropathies

Indexed keywords

INFLIXIMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DYSPNEA; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATITIS; SPONDYLOARTHROPATHY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPONDYLARTHROPATHIES; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 28544446753     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei085     Document Type: Article

References (15)

1. Dawes PT, Packham JC, Mucklow JC. TNF therapy for spondyloarthropathy: can we marshal the argument? Rheumatology 2004;43:1069-71.
2. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database Collaborative Arthritis Centres. J Rheumatol 2000;27:613-22.
3. Dougados M. Disease controlling antirheumatic therapy in Spondyloarthropathy. J Rheumatol 2001;28(Suppl. 62):16-20.
4. Gratacos J, Collado A, Filella X et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: A close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-31.
5. Braun J, Sieper J. Biologic therapies in the spondyloarthropathies - the current state. Rheumatology 2004;43:1072-84.
6. Breban M, Vignon E, Claudepierre P et al. Efficacy of Infliximab in refractory ankylosing spondylitis. Results of a six-month open-label study. Rheumatology 2002;41:1280-5.
7. Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
8. Maksymowych WP, Jhangry GS, Lambert RG et al. Infliximab in ankylosing spondylitis: An observational inception cohort. Analysis of efficacy and safety. J Rheumatol 2002;29:959-65.
9. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicenter trial. Lancet 2002;359:1187-93.
10. Braun J, Brandt J, Listing J, Rudwailet M, Sieper J. Biologic therapies in the spondyloarthropathies: New opportunities, new challenges. Curr Opin Rheumatol 2003;15:399-407.
11. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: An open pilot study. Ann Rheum Dis 2000;59:428-33.
12. Collantes-Estevez E, Muñoz-Villanueva MC, Cañete-Crespillo JD et al. Infliximab in refractory spondyloarthropathies: A multicenter 38 week open study. Ann Rheum Dis 2003;62:1239-40.
13. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumor necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
14. Anderson JJ, Baron G, Van der Heijde D, Nelson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
15. Braun J, Brandt J, Listing J et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Arthritis Rheum 2003;48:2224-33.